ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Ambrx, Astellas Eye Conjugate Drugs

by Michael McCoy
April 15, 2013 | APPEARED IN VOLUME 91, ISSUE 15

California-based Ambrx and Japan’s Astellas Pharma are joining to discover and develop antibody-drug conjugates for oncology. Ambrx will receive an up-front payment of $15 million from Astellas and could get up to $285 million in milestone payments. Ambrx creates ADCs using site-specific conjugation technology that allows the attachment of anticancer compounds to specific points on an antibody. It also has partnerships with Bristol-Myers Squibb, Eli Lilly & Co., and other firms.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment